SAN JOSE, Calif., Nov. 20, 2019 /PRNewswire/ -- Anixa
Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused
on harnessing the body's immune system in the fight against cancer,
today announced its collaboration with Idaho Urologic Institute, PA
(IUI) in the Cchek™ early cancer detection study. IUI will
provide patient samples for Anixa's ongoing prostate cancer study,
including support of clinical validation of Anixa's Cchek™ Prostate
Cancer Confirmation test.
IUI is one of several sites across the U.S. participating in
this study. Dr. Lisa Parillo
will serve as the Principal Investigator for the study at IUI.
Dr. Amit Kumar, Chief Executive
Officer of Anixa, stated, "We are pleased to have IUI join our
expanding group of Cchek™ collaboration partners. Our large
and growing team of influential collaborators has been key to the
development of our artificial intelligence driven liquid biopsy for
early cancer detection. We look forward to IUI's
participation as we continue the clinical validation phase of the
Cchek™ Prostate Cancer Confirmation test, in preparation for
commercial launch later this year."
About Cchek™
Cchek™ is an early cancer detection
technology, which measures a patient's immunological response to a
malignancy by analyzing immune system cells in peripheral
blood. The goal is to utilize the technology to determine a
patient's cancer status from a simple blood draw, eliminating the
need for a biopsy, which can be an expensive, painful and invasive
procedure. Further, conventional methods using current cancer
screening tests often lack accuracy and reliability. Anixa's
orthogonal approach using flow cytometry coupled with artificial
intelligence provides an alternative method with greater
affordability, efficacy and efficiency. To date, Anixa has
successfully used Cchek™ to detect the presence of 20 different
cancers including lung, colon, breast and prostate. The
robust cancer detection performance of Cchek™ makes it a platform
from which multiple cancer diagnostic tests may be developed.
The first such test, a prostate cancer confirmation test, is slated
for commercial launch by the end of 2019.
Idaho Urologic Institute, PA
Dedicated to providing
Idaho's most advanced urologic
care for men, women and children, the Idaho Urologic Institute was
established in 2005. The facility features an outpatient
surgery center, outpatient diagnostic imaging services, clinical
research department, full-service reference lab that includes a
comprehensive infertility lab, and a technologically advanced
radiation oncology care center.
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company focused on harnessing the
body's immune system in the fight against cancer. Anixa's
therapeutic portfolio includes a cancer vaccine technology focused
on the immunization against α-Lactalbumin to prevent triple
negative breast cancer (TNBC), as well as a cancer immunotherapy
program which uses a novel type of CAR-T, known as chimeric
endocrine receptor T-cell (CER-T) technology. The company's
diagnostic portfolio consists of Cchek™, a liquid biopsy technology
for early detection of solid tumors based on the body's immune
response to the presence of a malignancy. Anixa continually
examines emerging technologies in complementary fields for further
development and commercialization. Additional information is
available at www.anixa.com.
Forward-Looking Statements: Statements that
are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form
8-K. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law. You are cautioned not to unduly rely on such
forward-looking statements when evaluating the information
presented in this press release.
Anixa contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Tiberend Strategic Advisors, Inc.
Miriam Miller (Investors)
mmiller@tiberend.com
212-375-2694
Johanna Bennett (Media)
jbennett@tiberend.com
212-375-2686
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-announces-collaboration-with-idaho-urologic-institute-on-cchek-prostate-cancer-study-300961642.html
SOURCE Anixa Biosciences, Inc.